Global Anti-VEGF Ophthalmic Drug Market Research Report 2026

1 Anti-VEGF Ophthalmic Drug Market Overview
1.1 Product Definition
1.2 Anti-VEGF Ophthalmic Drug by Type
1.2.1 Global Anti-VEGF Ophthalmic Drug Market Value by Type: 2025 vs 2032
1.2.2 Pegaptanib
1.2.3 Ranibizumab
1.2.4 Aflibercept
1.2.5 Brolucizumab
1.2.6 Faricimab
1.3 Anti-VEGF Ophthalmic Drug by Application
1.3.1 Global Anti-VEGF Ophthalmic Drug Market Value by Application: 2025 vs 2032
1.3.2 Online Sales
1.3.3 Hospital
1.3.4 Clinic
1.3.5 Retail Pharmacy
1.3.6 Others
1.4 Global Anti-VEGF Ophthalmic Drug Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Ophthalmic Drug Revenue 2021–2032
1.4.2 Global Anti-VEGF Ophthalmic Drug Sales 2021–2032
1.4.3 Global Anti-VEGF Ophthalmic Drug Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Anti-VEGF Ophthalmic Drug Market Competition by Manufacturers
2.1 Global Anti-VEGF Ophthalmic Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Anti-VEGF Ophthalmic Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Anti-VEGF Ophthalmic Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Anti-VEGF Ophthalmic Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Anti-VEGF Ophthalmic Drug, Product Types and Applications
2.7 Global Key Manufacturers of Anti-VEGF Ophthalmic Drug, Date of Entry into the Industry
2.8 Global Anti-VEGF Ophthalmic Drug Market Competitive Situation and Trends
2.8.1 Global Anti-VEGF Ophthalmic Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Anti-VEGF Ophthalmic Drug Players Market Share by Revenue
2.8.3 Global Anti-VEGF Ophthalmic Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Anti-VEGF Ophthalmic Drug Market Scenario by Region
3.1 Global Anti-VEGF Ophthalmic Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Anti-VEGF Ophthalmic Drug Sales by Region: 2021–2032
3.2.1 Global Anti-VEGF Ophthalmic Drug Sales by Region: 2021–2026
3.2.2 Global Anti-VEGF Ophthalmic Drug Sales by Region: 2027–2032
3.3 Global Anti-VEGF Ophthalmic Drug Revenue by Region: 2021–2032
3.3.1 Global Anti-VEGF Ophthalmic Drug Revenue by Region: 2021–2026
3.3.2 Global Anti-VEGF Ophthalmic Drug Revenue by Region: 2027–2032
3.4 North America Anti-VEGF Ophthalmic Drug Market Facts & Figures by Country
3.4.1 North America Anti-VEGF Ophthalmic Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Anti-VEGF Ophthalmic Drug Sales by Country (2021–2032)
3.4.3 North America Anti-VEGF Ophthalmic Drug Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGF Ophthalmic Drug Market Facts & Figures by Country
3.5.1 Europe Anti-VEGF Ophthalmic Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Anti-VEGF Ophthalmic Drug Sales by Country (2021–2032)
3.5.3 Europe Anti-VEGF Ophthalmic Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-VEGF Ophthalmic Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Anti-VEGF Ophthalmic Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Anti-VEGF Ophthalmic Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific Anti-VEGF Ophthalmic Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-VEGF Ophthalmic Drug Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGF Ophthalmic Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Anti-VEGF Ophthalmic Drug Sales by Country (2021–2032)
3.7.3 Latin America Anti-VEGF Ophthalmic Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Anti-VEGF Ophthalmic Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGF Ophthalmic Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Anti-VEGF Ophthalmic Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa Anti-VEGF Ophthalmic Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGF Ophthalmic Drug Sales by Type (2021–2032)
4.1.1 Global Anti-VEGF Ophthalmic Drug Sales by Type (2021–2026)
4.1.2 Global Anti-VEGF Ophthalmic Drug Sales by Type (2027–2032)
4.1.3 Global Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2021–2032)
4.2 Global Anti-VEGF Ophthalmic Drug Revenue by Type (2021–2032)
4.2.1 Global Anti-VEGF Ophthalmic Drug Revenue by Type (2021–2026)
4.2.2 Global Anti-VEGF Ophthalmic Drug Revenue by Type (2027–2032)
4.2.3 Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Type (2021–2032)
4.3 Global Anti-VEGF Ophthalmic Drug Price by Type (2021–2032)
5 Segment by Application
5.1 Global Anti-VEGF Ophthalmic Drug Sales by Application (2021–2032)
5.1.1 Global Anti-VEGF Ophthalmic Drug Sales by Application (2021–2026)
5.1.2 Global Anti-VEGF Ophthalmic Drug Sales by Application (2027–2032)
5.1.3 Global Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2021–2032)
5.2 Global Anti-VEGF Ophthalmic Drug Revenue by Application (2021–2032)
5.2.1 Global Anti-VEGF Ophthalmic Drug Revenue by Application (2021–2026)
5.2.2 Global Anti-VEGF Ophthalmic Drug Revenue by Application (2027–2032)
5.2.3 Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Application (2021–2032)
5.3 Global Anti-VEGF Ophthalmic Drug Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Eyetech
6.1.1 Eyetech Company Information
6.1.2 Eyetech Description and Business Overview
6.1.3 Eyetech Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Eyetech Anti-VEGF Ophthalmic Drug Product Portfolio
6.1.5 Eyetech Recent Developments/Updates
6.2 Pfizer Inc
6.2.1 Pfizer Inc Company Information
6.2.2 Pfizer Inc Description and Business Overview
6.2.3 Pfizer Inc Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Pfizer Inc Anti-VEGF Ophthalmic Drug Product Portfolio
6.2.5 Pfizer Inc Recent Developments/Updates
6.3 Roche
6.3.1 Roche Company Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Roche Anti-VEGF Ophthalmic Drug Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Novartis Anti-VEGF Ophthalmic Drug Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Regeneron
6.5.1 Regeneron Company Information
6.5.2 Regeneron Description and Business Overview
6.5.3 Regeneron Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Regeneron Anti-VEGF Ophthalmic Drug Product Portfolio
6.5.5 Regeneron Recent Developments/Updates
6.6 Bayer
6.6.1 Bayer Company Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Bayer Anti-VEGF Ophthalmic Drug Product Portfolio
6.6.5 Bayer Recent Developments/Updates
6.7 Regeneron Pharmaceuticals
6.7.1 Regeneron Pharmaceuticals Company Information
6.7.2 Regeneron Pharmaceuticals Description and Business Overview
6.7.3 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Product Portfolio
6.7.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.8 Genentech
6.8.1 Genentech Company Information
6.8.2 Genentech Description and Business Overview
6.8.3 Genentech Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Genentech Anti-VEGF Ophthalmic Drug Product Portfolio
6.8.5 Genentech Recent Developments/Updates
6.9 Samsung Bioepis
6.9.1 Samsung Bioepis Company Information
6.9.2 Samsung Bioepis Description and Business Overview
6.9.3 Samsung Bioepis Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Samsung Bioepis Anti-VEGF Ophthalmic Drug Product Portfolio
6.9.5 Samsung Bioepis Recent Developments/Updates
6.10 Biogen
6.10.1 Biogen Company Information
6.10.2 Biogen Description and Business Overview
6.10.3 Biogen Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Biogen Anti-VEGF Ophthalmic Drug Product Portfolio
6.10.5 Biogen Recent Developments/Updates
6.11 Qilu Pharmaceutical
6.11.1 Qilu Pharmaceutical Company Information
6.11.2 Qilu Pharmaceutical Description and Business Overview
6.11.3 Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Product Portfolio
6.11.5 Qilu Pharmaceutical Recent Developments/Updates
6.12 Innovent Biologics
6.12.1 Innovent Biologics Company Information
6.12.2 Innovent Biologics Description and Business Overview
6.12.3 Innovent Biologics Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Innovent Biologics Anti-VEGF Ophthalmic Drug Product Portfolio
6.12.5 Innovent Biologics Recent Developments/Updates
6.13 Kanghong Pharmaceutical
6.13.1 Kanghong Pharmaceutical Company Information
6.13.2 Kanghong Pharmaceutical Description and Business Overview
6.13.3 Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Product Portfolio
6.13.5 Kanghong Pharmaceutical Recent Developments/Updates
6.14 Taikang Biology
6.14.1 Taikang Biology Company Information
6.14.2 Taikang Biology Description and Business Overview
6.14.3 Taikang Biology Anti-VEGF Ophthalmic Drug Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Taikang Biology Anti-VEGF Ophthalmic Drug Product Portfolio
6.14.5 Taikang Biology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGF Ophthalmic Drug Industry Chain Analysis
7.2 Anti-VEGF Ophthalmic Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGF Ophthalmic Drug Production Mode & Process Analysis
7.4 Anti-VEGF Ophthalmic Drug Sales and Marketing
7.4.1 Anti-VEGF Ophthalmic Drug Sales Channels
7.4.2 Anti-VEGF Ophthalmic Drug Distributors
7.5 Anti-VEGF Ophthalmic Drug Customer Analysis
8 Anti-VEGF Ophthalmic Drug Market Dynamics
8.1 Anti-VEGF Ophthalmic Drug Industry Trends
8.2 Anti-VEGF Ophthalmic Drug Market Drivers
8.3 Anti-VEGF Ophthalmic Drug Market Challenges
8.4 Anti-VEGF Ophthalmic Drug Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Anti-VEGF Ophthalmic Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Anti-VEGF Ophthalmic Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Anti-VEGF Ophthalmic Drug Market Competitive Situation by Manufacturers in 2025
Table 4. Global Anti-VEGF Ophthalmic Drug Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Anti-VEGF Ophthalmic Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Anti-VEGF Ophthalmic Drug Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Anti-VEGF Ophthalmic Drug Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Anti-VEGF Ophthalmic Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Anti-VEGF Ophthalmic Drug, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Anti-VEGF Ophthalmic Drug, Product Types and Applications
Table 12. Global Key Manufacturers of Anti-VEGF Ophthalmic Drug, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGF Ophthalmic Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Anti-VEGF Ophthalmic Drug Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGF Ophthalmic Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Anti-VEGF Ophthalmic Drug Sales by Region (K Units), 2021–2026
Table 18. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Region (2021–2026)
Table 19. Global Anti-VEGF Ophthalmic Drug Sales by Region (K Units), 2027–2032
Table 20. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Region (2027–2032)
Table 21. Global Anti-VEGF Ophthalmic Drug Revenue by Region (US$ Million), 2021–2026
Table 22. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Region (2021–2026)
Table 23. Global Anti-VEGF Ophthalmic Drug Revenue by Region (US$ Million), 2027–2032
Table 24. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Region (2027–2032)
Table 25. North America Anti-VEGF Ophthalmic Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Anti-VEGF Ophthalmic Drug Sales by Country (K Units), 2021–2026
Table 27. North America Anti-VEGF Ophthalmic Drug Sales by Country (K Units), 2027–2032
Table 28. North America Anti-VEGF Ophthalmic Drug Revenue by Country (US$ Million), 2021–2026
Table 29. North America Anti-VEGF Ophthalmic Drug Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Anti-VEGF Ophthalmic Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Anti-VEGF Ophthalmic Drug Sales by Country (K Units), 2021–2026
Table 32. Europe Anti-VEGF Ophthalmic Drug Sales by Country (K Units), 2027–2032
Table 33. Europe Anti-VEGF Ophthalmic Drug Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Anti-VEGF Ophthalmic Drug Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Anti-VEGF Ophthalmic Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Anti-VEGF Ophthalmic Drug Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Anti-VEGF Ophthalmic Drug Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Anti-VEGF Ophthalmic Drug Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Anti-VEGF Ophthalmic Drug Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Anti-VEGF Ophthalmic Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Anti-VEGF Ophthalmic Drug Sales by Country (K Units), 2021–2026
Table 42. Latin America Anti-VEGF Ophthalmic Drug Sales by Country (K Units), 2027–2032
Table 43. Latin America Anti-VEGF Ophthalmic Drug Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Anti-VEGF Ophthalmic Drug Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Anti-VEGF Ophthalmic Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Anti-VEGF Ophthalmic Drug Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Anti-VEGF Ophthalmic Drug Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Anti-VEGF Ophthalmic Drug Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Anti-VEGF Ophthalmic Drug Revenue by Country (US$ Million), 2027–2032
Table 50. Global Anti-VEGF Ophthalmic Drug Sales (K Units) by Type (2021–2026)
Table 51. Global Anti-VEGF Ophthalmic Drug Sales (K Units) by Type (2027–2032)
Table 52. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2021–2026)
Table 53. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2027–2032)
Table 54. Global Anti-VEGF Ophthalmic Drug Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Anti-VEGF Ophthalmic Drug Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Type (2021–2026)
Table 57. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Type (2027–2032)
Table 58. Global Anti-VEGF Ophthalmic Drug Price (US$/Unit) by Type (2021–2026)
Table 59. Global Anti-VEGF Ophthalmic Drug Price (US$/Unit) by Type (2027–2032)
Table 60. Global Anti-VEGF Ophthalmic Drug Sales (K Units) by Application (2021–2026)
Table 61. Global Anti-VEGF Ophthalmic Drug Sales (K Units) by Application (2027–2032)
Table 62. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2021–2026)
Table 63. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2027–2032)
Table 64. Global Anti-VEGF Ophthalmic Drug Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Anti-VEGF Ophthalmic Drug Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Application (2021–2026)
Table 67. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Application (2027–2032)
Table 68. Global Anti-VEGF Ophthalmic Drug Price (US$/Unit) by Application (2021–2026)
Table 69. Global Anti-VEGF Ophthalmic Drug Price (US$/Unit) by Application (2027–2032)
Table 70. Eyetech Company Information
Table 71. Eyetech Description and Business Overview
Table 72. Eyetech Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Eyetech Anti-VEGF Ophthalmic Drug Product
Table 74. Eyetech Recent Developments/Updates
Table 75. Pfizer Inc Company Information
Table 76. Pfizer Inc Description and Business Overview
Table 77. Pfizer Inc Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Pfizer Inc Anti-VEGF Ophthalmic Drug Product
Table 79. Pfizer Inc Recent Developments/Updates
Table 80. Roche Company Information
Table 81. Roche Description and Business Overview
Table 82. Roche Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Roche Anti-VEGF Ophthalmic Drug Product
Table 84. Roche Recent Developments/Updates
Table 85. Novartis Company Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Novartis Anti-VEGF Ophthalmic Drug Product
Table 89. Novartis Recent Developments/Updates
Table 90. Regeneron Company Information
Table 91. Regeneron Description and Business Overview
Table 92. Regeneron Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Regeneron Anti-VEGF Ophthalmic Drug Product
Table 94. Regeneron Recent Developments/Updates
Table 95. Bayer Company Information
Table 96. Bayer Description and Business Overview
Table 97. Bayer Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Bayer Anti-VEGF Ophthalmic Drug Product
Table 99. Bayer Recent Developments/Updates
Table 100. Regeneron Pharmaceuticals Company Information
Table 101. Regeneron Pharmaceuticals Description and Business Overview
Table 102. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Product
Table 104. Regeneron Pharmaceuticals Recent Developments/Updates
Table 105. Genentech Company Information
Table 106. Genentech Description and Business Overview
Table 107. Genentech Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Genentech Anti-VEGF Ophthalmic Drug Product
Table 109. Genentech Recent Developments/Updates
Table 110. Samsung Bioepis Company Information
Table 111. Samsung Bioepis Description and Business Overview
Table 112. Samsung Bioepis Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Samsung Bioepis Anti-VEGF Ophthalmic Drug Product
Table 114. Samsung Bioepis Recent Developments/Updates
Table 115. Biogen Company Information
Table 116. Biogen Description and Business Overview
Table 117. Biogen Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Biogen Anti-VEGF Ophthalmic Drug Product
Table 119. Biogen Recent Developments/Updates
Table 120. Qilu Pharmaceutical Company Information
Table 121. Qilu Pharmaceutical Description and Business Overview
Table 122. Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Product
Table 124. Qilu Pharmaceutical Recent Developments/Updates
Table 125. Innovent Biologics Company Information
Table 126. Innovent Biologics Description and Business Overview
Table 127. Innovent Biologics Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Innovent Biologics Anti-VEGF Ophthalmic Drug Product
Table 129. Innovent Biologics Recent Developments/Updates
Table 130. Kanghong Pharmaceutical Company Information
Table 131. Kanghong Pharmaceutical Description and Business Overview
Table 132. Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Product
Table 134. Kanghong Pharmaceutical Recent Developments/Updates
Table 135. Taikang Biology Company Information
Table 136. Taikang Biology Description and Business Overview
Table 137. Taikang Biology Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Taikang Biology Anti-VEGF Ophthalmic Drug Product
Table 139. Taikang Biology Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Anti-VEGF Ophthalmic Drug Distributors List
Table 143. Anti-VEGF Ophthalmic Drug Customers List
Table 144. Anti-VEGF Ophthalmic Drug Market Trends
Table 145. Anti-VEGF Ophthalmic Drug Market Drivers
Table 146. Anti-VEGF Ophthalmic Drug Market Challenges
Table 147. Anti-VEGF Ophthalmic Drug Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report


List of Figures
Figure 1. Product Picture of Anti-VEGF Ophthalmic Drug
Figure 2. Global Anti-VEGF Ophthalmic Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Anti-VEGF Ophthalmic Drug Market Share by Type: 2025 & 2032
Figure 4. Pegaptanib Product Picture
Figure 5. Ranibizumab Product Picture
Figure 6. Aflibercept Product Picture
Figure 7. Brolucizumab Product Picture
Figure 8. Faricimab Product Picture
Figure 9. Global Anti-VEGF Ophthalmic Drug Market Value by Application (US$ Million), 2021–2032
Figure 10. Global Anti-VEGF Ophthalmic Drug Market Share by Application: 2025 & 2032
Figure 11. Online Sales
Figure 12. Hospital
Figure 13. Clinic
Figure 14. Retail Pharmacy
Figure 15. Others
Figure 16. Global Anti-VEGF Ophthalmic Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Anti-VEGF Ophthalmic Drug Market Size (US$ Million), 2021–2032
Figure 18. Global Anti-VEGF Ophthalmic Drug Sales (K Units), 2021–2032
Figure 19. Global Anti-VEGF Ophthalmic Drug Average Price (US$/Unit), 2021–2032
Figure 20. Anti-VEGF Ophthalmic Drug Report Years Considered
Figure 21. Anti-VEGF Ophthalmic Drug Sales Share by Manufacturers in 2025
Figure 22. Global Anti-VEGF Ophthalmic Drug Revenue Share by Manufacturers in 2025
Figure 23. Top 5 and Top 10 Global Anti-VEGF Ophthalmic Drug Players: Market Share by Revenue in Anti-VEGF Ophthalmic Drug in 2025
Figure 24. Anti-VEGF Ophthalmic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 25. Global Anti-VEGF Ophthalmic Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 26. North America Anti-VEGF Ophthalmic Drug Sales Market Share by Country (2021–2032)
Figure 27. North America Anti-VEGF Ophthalmic Drug Revenue Market Share by Country (2021–2032)
Figure 28. United States Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Canada Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Europe Anti-VEGF Ophthalmic Drug Sales Market Share by Country (2021–2032)
Figure 31. Europe Anti-VEGF Ophthalmic Drug Revenue Market Share by Country (2021–2032)
Figure 32. Germany Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. France Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. U.K. Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Italy Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Russia Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Asia Pacific Anti-VEGF Ophthalmic Drug Sales Market Share by Region (2021–2032)
Figure 38. Asia Pacific Anti-VEGF Ophthalmic Drug Revenue Market Share by Region (2021–2032)
Figure 39. China Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Japan Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. South Korea Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. India Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Australia Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. China Taiwan Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Southeast Asia Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Latin America Anti-VEGF Ophthalmic Drug Sales Market Share by Country (2021–2032)
Figure 47. Latin America Anti-VEGF Ophthalmic Drug Revenue Market Share by Country (2021–2032)
Figure 48. Mexico Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Brazil Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Argentina Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Colombia Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Middle East and Africa Anti-VEGF Ophthalmic Drug Sales Market Share by Country (2021–2032)
Figure 53. Middle East and Africa Anti-VEGF Ophthalmic Drug Revenue Market Share by Country (2021–2032)
Figure 54. Turkey Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Saudi Arabia Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. UAE Anti-VEGF Ophthalmic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Global Sales Market Share of Anti-VEGF Ophthalmic Drug by Type (2021–2032)
Figure 58. Global Revenue Market Share of Anti-VEGF Ophthalmic Drug by Type (2021–2032)
Figure 59. Global Anti-VEGF Ophthalmic Drug Price (US$/Unit) by Type (2021–2032)
Figure 60. Global Sales Market Share of Anti-VEGF Ophthalmic Drug by Application (2021–2032)
Figure 61. Global Revenue Market Share of Anti-VEGF Ophthalmic Drug by Application (2021–2032)
Figure 62. Global Anti-VEGF Ophthalmic Drug Price (US$/Unit) by Application (2021–2032)
Figure 63. Anti-VEGF Ophthalmic Drug Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit